Lupin has inked a licensing pact for the commercialisation and marketing of Ranibizumab, a biosimilar of Lucentis, in various countries inc...

Total expenses in the quarter were marginally higher at Rs 2,797.66 crore, as against Rs 2,727.71 crore in the same period a year ago, the ...

The randomised trial of 52 weeks was conducted in 11 countries and included over 500 patients, Lupin said.

The Indian biogenerics industry is poised to exploit the opportunity they did in the case of generics, although it has no clear advantage a...

Dr Reddy’s was among the first to race off the blocks with four launches in India about as many years. But things have slowed since.

Intas is the only domestic firm with two biosimilars filed for registration in the US and it looks to deliver affordable and innovative pha...